Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphoma

[Oncoinfo – Istantanee di Oncologia: seguici su http://oncoinfo.it] The SWOG S1826 trial could change the treatment of classic Hodgkin lymphoma forever. Why and how? We asked Alex Francisco Herrera (Associate Professor, Division Of Lymphoma - City of Hope National Medical Center, Duarte) at ASCO 2023, in Chicago. He explained us how N-AVD improved PFS vs BV-AVD in pts with AS HL.